SHANGHAI – Privately held Shanxi Taxus Pharmaceuticals Co. Ltd., a subsidiary of Shenzhen Forntsea Taxus Industry Capital Management, will acquire majority shares in innovative drug developer Cardium Therapeutics Inc. (CRXM), of San Diego, for $5 million in cash.